ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours
C. Coyle(MRC Clinical Trials Unit at UCL), Ruth E. Langley(MRC Clinical Trials Unit at UCL), Alistair Ring(Brighton and Sussex Medical School), Lindy Berkman, Mairead MacKenzie(The Patients Association), Samuel Rowley(MRC Clinical Trials Unit at UCL), Fay Cafferty(MRC Clinical Trials Unit at UCL), C.S. Pramesh(Homi Bhabha National Institute), Richard H. Wilson(Queen's University Belfast), Sudeep Gupta(Tata Memorial Hospital), Duncan C. Gilbert(Royal Sussex County Hospital), Howard Kynaston(Cardiff University), David Cameron(Edinburgh Cancer Research)
Cited by 162
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830